Clinical Trial Details

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Categories (click each to see list of all clinical trials associated with that category): Pediatric (PEDONC)

Current Status: Open

Phase: II (Cancer Control)

Principal Investigator: Beck, Jill

Eligibility: https://clinicaltrials.gov/study/NCT04195555?term=NCT04195555&rank=1

Summary
PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with AG-120 (ivosidenib) with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in the IDH1 pathway.